Patent classifications
A23L33/10
Hexylamine salts and methods of using hexylamine
Salts of hexylamine, for example, hexylamine succinate and tri-hexylamine citrate and their method of production are described. The disclosure also relates to compositions comprising hexyalmine, for example, for reducing appetite in a human subject, treating obesity in a human subject, preventing obesity in a human subject, preventing weight gain in a human subject, increasing fat loss in a human subject, treating an overweight human subject, increasing athletic performance in a human subject, increasing endurance in a human subject, increasing muscle strength in a human subject, improving cognitive function in a human subject, treating ADHD in a human subject, increasing sweating in a human subject, reducing reaction time of a human subject, increasing psychomotor vigilance of a human subject, enhancing memory in a human subject, increasing central nervous system activity in a human subject, and enhancing alertness, attention, concentration, and/or memory in a human subject.
COMPOSITIONS FOR USE IN THE REDUCTION OF PAIN AND/OR PERCEPTION OF PAIN IN INFANTS AND YOUNG CHILDREN
The present invention relates to compositions comprising a mix of human milk oligosaccharides consisting of 2′-fucosyllactose and difucosyllactose, for use in the reduction of pain and/or perception of pain in an infant or in a young child. The compositions are particularly effective in the restoration of the sensitivity of the bi-directional pain transmission pathways in the gut-brain axis to normal levels. The compositions are in particular useful in reducing abdominal pain, such as pain associated with gastrointestinal discomfort, functional gastrointestinal disorders, and/or gastrointestinal diseases and consequently also contribute to reducing the crying periods and to improving the quality of sleep, the general quality of life, the mood, the playfulness, the temperament and/or the happiness of the infants and young children.
a-GLUCOSIDASE INHIBITOR, INVERTASE INHIBITOR, AND SUGAR ABSORPTION INHIBITOR
[Object] To provide a composition having an excellent α-glucosidase inhibitory effect or invertase inhibitory effect.
[Solution] A compound (I) contains a compound represented by a structural formula described below as an active ingredient,
##STR00001##
a-GLUCOSIDASE INHIBITOR, INVERTASE INHIBITOR, AND SUGAR ABSORPTION INHIBITOR
[Object] To provide a composition having an excellent α-glucosidase inhibitory effect or invertase inhibitory effect.
[Solution] A compound (I) contains a compound represented by a structural formula described below as an active ingredient,
##STR00001##
DRIED KUDZU FLOWER POWDER AND FOOD PRODUCT COMPRISING DRIED KUDZU FLOWER POWDER
The present invention is a food product comprising dried Kudzu flower powder, and having a water content of 8% by weight or less, and preferably which proportion of fractions passing a sieve having a sieve opening of 2 mm is 20% by weight or more. The food product of the present invention has good taste and odor.
DRIED KUDZU FLOWER POWDER AND FOOD PRODUCT COMPRISING DRIED KUDZU FLOWER POWDER
The present invention is a food product comprising dried Kudzu flower powder, and having a water content of 8% by weight or less, and preferably which proportion of fractions passing a sieve having a sieve opening of 2 mm is 20% by weight or more. The food product of the present invention has good taste and odor.
COMPOSITION, COMPRISING VINEGAR PICKLED EGG AS ACTIVE INGREDIENT, FOR PREVENTION, ALLEVIATION, OR TREATMENT OF DIABETIC FOOT ULCER
The present invention relates to a composition, comprising a vinegar pickled egg as an active ingredient, for prevention, alleviation, or treatment of diabetic foot ulcer. More specifically, a vinegar pickled egg fermentate obtained by adding and fermentating egg white of pullet eggs with medicinal herb vinegar does not irritate the skin and is effective for alleviating diabetic foot ulcer, thus being able to find advantageous applications as a therapeutic agent for diabetic foot ulcer, an anti-diabetic foot ulcer skin preparation for external use, or a substance for a health functional food for prevention or alleviation of diabetic foot ulcer.
COMPOSITION FOR PREVENTING OR TREATING OCULAR DISEASES COMPRISING AMNIOTIC EPITHELIAL CELL DERIVED EXOSOMES
The present invention relates to a composition comprising amniotic epithelial cell-derived exosomes as an active ingredient for prevention or treatment of ocular diseases and, more specifically, to a pharmaceutical composition for prevention or treatment of ocular diseases and a health functional food composition for prevention or alleviation of ocular diseases, each composition comprising amniotic epithelial cell-derived exosomes as an active ingredient. The amniotic epithelial cell-derived exosomes have ability to heal wounds on ocular tissues, recover the lacrimal gland destroyed by ocular diseases to induce lacrimation, and reduce the secretion of various inflammatory cytokines, thereby further effectively preventing or treating ocular diseases.
Protein products and methods for making the same
According to one embodiment, a protein product may include a mixture of water and particulate matter comprising protein. The mixture may include medium chain aldehydes and pyrazines. The ratio of a total concentration of medium chain aldehydes in the mixture to a total concentration of pyrazines in the mixture, as determined by gas chromatography-mass spectrometry, may be greater than or equal to 0.5 and less than or equal to 45. The mixture may also include from about 0.5 wt. % to about 8.0 wt. % total protein by weight of the mixture. In addition, the mixture may include from about 40 wt. % to about 98 wt. % water by weight of the mixture and less than or equal to about 4.0 wt. % oil and fat by weight of the mixture. The particulate matter may have an average particle size less than or equal to about 50 μm.
Protein products and methods for making the same
According to one embodiment, a protein product may include a mixture of water and particulate matter comprising protein. The mixture may include medium chain aldehydes and pyrazines. The ratio of a total concentration of medium chain aldehydes in the mixture to a total concentration of pyrazines in the mixture, as determined by gas chromatography-mass spectrometry, may be greater than or equal to 0.5 and less than or equal to 45. The mixture may also include from about 0.5 wt. % to about 8.0 wt. % total protein by weight of the mixture. In addition, the mixture may include from about 40 wt. % to about 98 wt. % water by weight of the mixture and less than or equal to about 4.0 wt. % oil and fat by weight of the mixture. The particulate matter may have an average particle size less than or equal to about 50 μm.